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JNKIt is becoming evident that chronic exposure to stress not only might result in insulin resistance or cognitive def-
icits, but may also be considered a risk factor for pathologies such as depression or Alzheimer's disease (AD).
There is great interest in determining the molecular mechanisms underlying interactions between stress,
aging, memory and Alzheimer's disease (AD). We have used the chronic mild stress (CMS) model to study the
effects of chronic stress on the aging process and the development of central insulin resistance and AD pathology.
CMS aged mice showed cognitive impairments in the novel object recognition test. In addition, CMS aged mice
displayed both peripheral insulin resistance, as shown by HOMA index, and decreased hippocampal levels of
pIRS and downstream intracellular signaling (pAKT, pGSK and pERK1/2). Interestingly, therewas a signiﬁcant in-
crease in both C99:C83 ratio and BACE1 levels in the hippocampus of CMS agedmice. Increased expression of the
ADmarker pTauwas also found in stressed agedmice. Increased expression of the stress-activated protein kinase
JNK was found in CMS aged mice, accompanied by signiﬁcant decreases in glucocorticoid receptor (GR) expres-
sion and increases in mineralocorticoid receptor (MR) expression. It is suggested that the interaction of stress
with aging should be considered when studying determinants of the onset and progression of AD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Stress is believed to contribute to the variability of the aging process
and to the development of age-related neuro- and psychopathologies
[1,2]. Clinical data have identiﬁed stressful lifestyle or stress-related
psychiatric disorders (i.e. major depression) as risk factors for develop-
ing Alzheimer's disease [3,4]. There is widespread recognition in the ur-
gency to understand the causes and mechanisms of AD because up to
now, all attempts to ﬁnd a cure for the disease have failed. It is becoming
increasingly clear that a concerted action for ﬁghting the AD epidemic
must be based on taking action against its risk factors. Senescence is
the major risk factor for sporadic AD. Although there is evident interest
in studying theways inwhich stressmight affect the aging process, very
few published papers have focused on this task. There continues to be
interest in understanding the mechanisms responsible for interactions
among stress, aging and memory.
The effects of stress are thought to be mediated by the activation of
the hypothalamic–pituitary–adrenal (HPA) axis, culminating in in-
creased levels of glucocorticoids [5]. Aged rats aswell as elderly humans
show progressive loss of control of the HPA axis [6], although thisical Research, Department of
/Irunlarrea, 1, 31008 Pamplona,
ights reserved.statement is also controversial [7]. Glucocorticoid actions are mediated
by two ligand-dependent transcription factors, the glucocorticoid re-
ceptor (GR) and the mineralocorticoid receptor (MR). The hippocam-
pus has a rich abundance of GRs and through their actions this brain
area serves as an integral part of the feedback loop responsible for ter-
minating glucocorticoid release during the stress response [2,8]. Thus,
chronic stress could lead to hippocampal atrophy and further HPA
axis disinhibition.
Themechanisms underlying the effects of stress levels remain large-
ly unknown. Exposure to stress levels of glucocorticoids produces phys-
iological responses that are characteristic of type 2 diabetes, such
as peripheral insulin resistance; corticosterone administration has
been shown to impair insulin signaling in the rat hippocampus [9].
These effects may contribute to the deleterious consequences of
hypercortisolemic/hyperglycemic states observed in type 2 diabetes.
On the other hand, it has been suggested that cognitive impairment in
diabetes may be a glucocorticoid-mediated effect because an elevation
of circulating corticosterone is thought to be associated with memory
impairments [10–12]. Stress and insulin resistance have been suggested
to contribute not only to age-related loss of neurons in thehippocampus
of rats [13], but also to the development of lesions typical of AD [14]. In
fact, stress and glucocorticoids have been shown to exacerbate AD-like
neuropathology [15–17].
The aim of this study was to determine the molecular mechanisms
involved in chronic stress-induced insulin resistance and memory
2333M. Solas et al. / Biochimica et Biophysica Acta 1832 (2013) 2332–2339impairment in aging, aswell as to determine the contribution of chronic
stress in adulthood to the development of AD-related markers in aged
mice. This study points to a key role of the stress-activated kinase JNK
in the effects of chronic stress in aging.2. Material and methods
2.1. Animals and experimental design
C57BL/6J mice were divided into the following groups: controls
(3 months), aged (24 months) and stressed aged mice (24 months).
The chronic mild stress (CMS) procedure (6 weeks) was applied to
mice aged 19 months at the beginning of the CMS procedure. Four
months after the cessation of the stress, cognitive testing was carried
out and the mice were sacriﬁced. Increased mortality was found in
aged mice (30% mortality), especially in the CMS group (42%). Conse-
quently, the number of mice in the aged group and in the CMS aged
group was lower than expected. At the time of behavioral testing, the
number of animals was n = 10 (controls), n = 7 (aged mice) and
n = 7 (CMS aged mice).
The animals were housed in a temperature- (21 ± 1 °C) and
humidity- (55 ± 5%) controlled room on a 12-h light/dark cycle. All
the experiments were carried out in strict compliance with the recom-
mendations of the EU (DOCE L 358/1 18/2/1986) for the care and use
of laboratory animals. Every effort was made to minimize the number
of animals used and possible suffering.2.2. Chronic mild stress (CMS) procedure
Unpredictable repeatedmild stressors were applied for 6 weeks fol-
lowing the protocol described byHarkin et al. [18]withminormodiﬁca-
tions [19]. Brieﬂy, the following stressors (two–three in any 24 h
period) were applied: low intensity stroboscopic illumination (in dark,
8 h), intermittent bell (10 dB, 1/10 s), white noise (an untuned radio,
4 h), rat odor (sawdust from rat cages, 8 h), cage tilt at 45° (8 h), soiled
bedding (6 h), paired housing (with new partner, 2 h), novel object in
the home cage (3 h), water and food deprivation (8 h), overnight illu-
mination and removal of nesting material (12 h), and conﬁnement in
a small cage (80 cm3, 1 h).2.3. Cognitive testing: novel object recognition test (NORT)
One day prior to the test, locomotor activity was measured for
30 min in an open ﬁeld, which consisted of four square arenas
(65 × 65 × 45 cm3)made of blackwood, using a video tracking system
(Ethovision 3.0, Noldus Information Technology B.V., The Netherlands),
in a softly illuminated room. Total path length (cm) was analyzed.
The test was performed as previously described [10]. The open ﬁeld
consisted of a square open ﬁeld (65 × 65 × 45 cm3) made of black
wood. During the ﬁrst trial of the experiment (sample trial), two objects
(prisms, conical tubesweightedwith colored sand or small objectswere
constructed using Lego® blocks) similar in shape, size, color, texture,
etc., equidistant from the sides (10 cm) were placed within the cham-
ber. The animal was placed in the center of the open-ﬁeld and allowed
to freely explore for 5 min. It was considered that the animal was ex-
ploring the object when the head of the mouse was oriented toward
the object with its nose within 2 cm of the object. One or 24 h later a
second trial (test trial) took place, in which one object was replaced
by a different one, and exploration was scored for 5 min. In order to
eliminate olfactory stimuli, chamber and objects were cleaned after
testing each animal. To avoid preference for one of the objects, the
order of the objects was balanced between testing animals. Results
were expressed as percentage of time spent with the novel object
with respect to the total exploration time (discrimination index).2.4. Tissue and blood collection
Two days after completion of behavioral studies, fasting animals
(15 h) were sacriﬁced by decapitation between 0800 h and 1000 h.
Brains were removed, dissected on ice and stored at −80 °C. Trunk
blood was collected into EDTA tubes, centrifuged at 1250 ×g (15 min,
4 °C), and plasma was frozen.
Plasma corticosterone (50 μL) was determined using a commercially
available solid-phase 125I radioimmunoassaykit (Coat-a-Count, Siemens,
USA).
Insulin and glucose were measured in plasma samples using the
Sensitive Insulin enzyme immunoassay kit (EZRMI-13K, Millipore,
Billerica, MA) and Glucose GOD-PAP enzyme immunoassay kit (Roche
Diagnostics, Spain) respectively.
Insulin sensitivity was analyzed by assessing the homeostatic model
assessment (HOMA) index [20,21]. HOMA index is expressed as insulin
(μU/mL) × glucose (mg/dL) / 405.
2.5. Western blotting
Assays were performed in hippocampal tissue as previously de-
scribed [22]. Details on conditions used in Western blotting experi-
ments are shown in Table 1. In all cases, immunopositive bands were
visualized using an enhanced chemiluminescence Western blotting de-
tection reagent (ECL; Amersham, Buckinghamshire, England). The opti-
cal density of reactive bands visible on X-ray ﬁlm was determined
densitometrically. β-Actin was used as the internal control. Results
were calculated as the percentage of OD values of control, and when
stated, normalized to total levels of non-phosphorylated protein.
2.6. Aβ levels
Aβ1–42 levels were determined using a commercially available high
sensitivity ELISA kit (Wako Pure Chemical Industries, Tokyo, Japan) fol-
lowing manufacturer's instructions.
2.7. Data analysis
Data were analyzed by SPSS for Windows, version 15.0. Normality
was checked by Shapiro–Wilk's test (p b 0.05). Data was analyzed by
one-way ANOVA followed by Scheffe's test or by Student's t-test.
3. Results
3.1. Effects of stress on cognition
As shown in Fig. 1, with a 24-h interval between the sample and the
test phase, recognition memory was signiﬁcantly impaired by both
aging and CMS [F2,23 = 12.069, p b 0.001; n = 7–10]. Aged mice
(p b 0.05) and CMS aged mice (p b 0.001) showed learning impair-
ment compared to the control young group, as the discrimination
index in the NORT was signiﬁcantly lower. Although no signiﬁcant
effects were found in the 1-h interval paradigm [F2,23 = 2.166, p =
0.136; n = 7–10], a strong tendency in CMS aged mice (vs. control
young group) was found (p = 0.08). In order to highlight the contribu-
tion of CMS to cognitive impairments, and differentiate it from the ef-
fects of aging, data was re-analyzed comparing data from the aged
group with the CMS aged group using a Student's t-test. Signiﬁcant dif-
ferences were found in aged mice vs. CMS aged groups in the 1-h inter-
val paradigm (p b 0.05), and a strong tendency was also found in the
24-h interval (p b 0.08). It should be noted that due to the increased
mortality in the CMS aged group, the size of this group is relatively
small, which probably contributed to the high variability in the results.
The effects observed in NORT do not appear to be associated with
differences in locomotor activity, as total distance traveled in the open
ﬁeld did not differ between groups (data not shown, F2,23 = 0.520,
Table 1
Conditions used in Western blotting experiments.
Antibody Dilution Source Molecular
weight
pIR (Y1361) (1:500) Abcam, Cambridge, MA, USA 90 kDa
Total IR (1:500) Cell Signaling Technology, MA, USA. 90 kDa
pIRS1 (Ser636/639) (1:1000) Cell Signaling Technology, MA, USA. 180 kDa
Total IRS1 (1:1000) Cell Signaling Technology, MA, USA. 180 kDa
pAkt (Ser473) (1:1000) Cell Signaling Technology, MA, USA. 60 kDa
Total Akt (1:1000) Cell Signaling Technology, MA, USA. 60 kDa
pGSK3β (Ser9) (1:1000) Cell Signaling Technology, MA, USA. 46 kDa
Total GSK3β (1:1000) Cell Signaling Technology, MA, USA. 46 kDa
pERK 1/2
(Thr202/Tyr204)
(1:1000) Cell Signaling Technology, MA, USA. 42/44 kDa
Total ERK 1/2 (1:2000) Cell Signaling Technology, MA, USA. 42/44 kDa
pTau (AT8)
(Ser202/Thr205)
(1:1000) Pierce, Rockford, IL, USA 40–50 kDa
Total tau (T46) (1:3000) Sigma-Aldrich, St. Louis, MO, USA 40–50 kDa
GR (1:2000) Santa Cruz Biotechnology, CA, USA 95 kDa
MR (1:500) Abcam, Cambridge, MA, USA 107 kDa
pJNK
(Thr183/Tyr185)
(1:500) Cell Signaling Technology, MA, USA. 46/54 kDa
Total JNK (1:500) Cell Signaling Technology, MA, USA. 46/54 kDa
IR: insulin receptor; IRS: insulin receptor substrate; GR: glucocorticoid receptor; MR:
mineralocorticoid receptor.
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groups in the discrimination index in the sample trial in the NORT
(data not shown, F2,23 = 0.474, p = 0.632; n = 7–10).
3.2. Effects of stress on HPA axis
As depicted in Fig. 2A, basal plasma corticosterone was signiﬁcantly
increased in CMS aged mice compared to both aged and control young
groups [F2,23 = 3.522, p b 0.05; n = 7–10].
Signiﬁcant decreases in GR expression were found in the hippocam-
pus of CMS aged mice compared to either controls or aged mice
[F2,15 = 10.918, p b 0.001; n = 5–6] (Fig. 2B). MR expression was sig-
niﬁcantly increased only in the CMS agedmice [F2,15 = 7.081, p b 0.01;
n = 5–6] (Fig. 2C).
3.3. Effects of stress on insulin signaling in aged mice
As chronic exposure to stressmay lead to insulin resistance, we have
studied the effects of CMS on insulin levels and associated intracellular
pathways in aged mice. Fasting insulin levels were signiﬁcantly in-
creased [F2,23 = 19.983, p b 0.001; n = 7–10] (Fig. 3A) in CMS aged
mice compared to both control and aged mice (p b 0.001 in both
cases). Glucose levels [F2,23 = 7.994, p b 0.01; n = 7–10] (Fig. 3B)
and HOMA index [F2,23 = 24.023, p b 0.001; n = 7–10] (Fig. 3C)Fig. 1. Effects of chronic stress (CMS) on cognitive performance in aged mice. Data shows
discrimination index (time exploring the new object / total exploration time × 100) in
the novel object recognition test. *p b 0.05, ***p b 0.001, Scheffe's multiple-comparison
test.
Fig. 2. Effects of chronic stress (CMS) on HPA axis in aged mice. In panel A, the effects of
chronic stress (CMS) on levels of plasma corticosterone (CORT) in aged mice were
shown. In panel B, the effects of chronic stress (CMS) on glucocorticoid receptor (GR)
levels in aged mice were shown. In panel C, the effects of chronic stress (CMS) on miner-
alocorticoid receptor (MR) levels in agedmicewere shown. *p b 0.05, **p b 0.01, Scheffe's
multiple-comparison test.were altered according to insulin level variations. Interestingly, HOMA
index in aged mice was similar to controls. Therefore, CMS aged mice
showed signs of peripheral insulin resistance.
Fig. 3. Effects of chronic stress (CMS) on insulin resistance in aged mice. Peripheral (plasma) insulin (panel A) and glucose (panel B) levels. Panel C shows HOMA index (insulin
(μU/mL) × glucose (mg/dL) / 405). Panels D and E show percentage of optical density (O.D.) values of control young mice and representative picture of the blotting. **p b 0.01,
***p b 0.001, Scheffe's multiple-comparison test.
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creased levels of insulin receptor phosphorylation (Fig. 3D) was found
in CMS aged mice. Interestingly, the phosphorylation status of the
adapter protein insulin receptor substrate 1 (IRS1) at the active site
(Ser636/639) was signiﬁcantly reduced in the CMS aged group com-
pared to control and aged mice ([F2,15 = 31.995, p b 0.001; n = 5–6],Fig. 4. Involvement of stress activated protein kinase JNK. Data shows effects of chronic stress (C
test.Scheffe's multiple-comparison, p b 0.001) (Fig. 3E). The stress-activate
kinase JNK [23] phosphorylates the insulin receptor substrate 1 (IRS1)
at an inhibitory site that can block signal transduction by the insulin re-
ceptor [24], therefore purportedly altering insulin-related intracellular
pathways, namely the Akt–GSK3β–Tau pathway. There was a signiﬁ-
cant increase in levels of phosphorylated JNK (pJNK) [F2,15 = 7.364,MS) on phosphorylated JNK levels in aged mice. *p b 0.05, Scheffe's multiple-comparison
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(p b 0.05) and aged (p b 0.05) groups (Fig. 4).
When studying the insulin-triggered pathways, decreased levels of
phosphorylated Akt (pAkt) were found in both aged and CMS aged
mice [F2,15 = 9.032, p b 0.01; n = 5–6] (Fig. 5A). GSK3β is inactivated
byphosphorylation by pAkt, leading to increased active formwhen total
levels are not modiﬁed. GSK3βwas found to be signiﬁcantly decreased
in only the CMS aged group ([F2,15 = 7.814, p b 0.05; n = 5–6],
Scheffe's multiple-comparison test, p b 0.05) (Fig. 5B). GSK3β is re-
sponsible for phosphorylating Ser202 of tau protein [25]. As depicted
in Fig. 5C, there was a signiﬁcant increase on tau phosphorylation in
both the CMS and CMS aged groups [F2,15 = 12.898, p b 0.01; n = 5–
6]. Even though there was a trend toward increases in pTau in the
CMS aged group compared to the aged group (p = 0.08), this increase
did not reached statistical signiﬁcance.
Insulin binding to insulin receptors also activates another signal
transduction cascade identiﬁed as theMAPK/ERKpathway. A signiﬁcant
effect in pERK1 [F2,15 = 5.129, p b 0.05; n = 5–6] and in pERK2 levels
[F2,15 = 4.146, p b 0.05; n = 5–6]was found (Fig. 5D). Further analysis
showed signiﬁcant decreases in pERK1 (p b 0.05) and pERK2 (p b 0.05)
in CMS aged mice compared with controls.
Consistent with a post-transcriptional regulation of these enzymes,
total insulin receptor, IRS1, Akt, GSK3β, tau and ERK1/2 protein levels,
normalized using actin, remained unaltered.
3.4. Effects of stress on APP processing in aged mice
As depicted in Fig. 6A, APP protein levels were not affected by either
aging or stress aging [F2,15 = 0.131, p N 0.05; n = 5–6]. When analyz-
ing the amyloidogenic route (Fig. 6C), signiﬁcant increases in the C99:
C83 ratio were found in stress aged mice [F2,15 = 5.276, p b 0.05;Fig. 5. Effects of chronic stress (CMS) on insulin downstream signaling pathways (panels A to
representative picture of the blotting. *p b 0.05, **p b 0.01, Scheffe's multiple-comparison testn = 5–6], and BACE1 levels were signiﬁcantly increased in CMS aged
group compared to controls [F2,15 = 6.341, p b 0.05; n = 5–6]
(Fig. 6B). Even though Aβ42 levels (Fig. 6D) appear to be higher in the
CMSaged group, these data did not reach statistical signiﬁcance, probably
due to the high variability of the data [F2,15 = 1.052, p N 0.05; n = 5–6].
4. Discussion
Exposure to stress might have deleterious effects on brain structure
and function,which could bemanifested either immediately after stress
exposure [8] or as a long-term vulnerability later in life [1]. It iswell doc-
umented that chronic elevation of circulating corticosterone concentra-
tions by stress exerts an inhibitory inﬂuence on learning and memory
retrieval [10,12]. However, so far the studies on lasting consequences
of stress exposure have generally been restricted to the early postnatal
period [22], adolescence [26] or chronic stress during mid-life [27,28].
Animals exposed to CMShave been described to show signs of increased
activity in the HPA axis, behavioral (depressive-like behavior) alter-
ations and cognitive deﬁcits that may persist up to one month after
the cessation of stress [19]. Down-regulation of GRs by blocking the
negative feedback on the HPA axis would contribute to maintaining an
altered response to stress. The ﬁnding of signiﬁcant long-lasting effects
(4 months after the cessation of stress) of CMS on cognition in aged
mice leads us to propose that chronic exposure to stress might acceler-
ate senescent hippocampal degeneration. Supporting this hypothesis is
the important increase in mortality that was found in agedmice, partic-
ularly those subjected to CMS. However, this increasedmortality has led
to a decrease in sample size in this study, and therefore, data from cog-
nitive studies should be cautiously considered.
Taking into account the fact that aging per se does not appear to alter
MR expression [29], the fact that this study showed increased levels ofD). All panels show percentage of optical density (O.D.) values of control young mice and
.
Fig. 6. Effects of chronic stress (CMS) on APP processing. Panels A to C show percentage of optical density (O.D.) values of control young mice and representative picture of the blotting.
Panel D shows Aβ1–42 levels (pmol/mg). *p b 0.05, **p b 0.01, Scheffe's multiple-comparison test.
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be noted that regulation of MR expression appears to depend on the
type of stress (social vs. environmental [30]) and time course of exposi-
tion to elevated corticosterone levels (adolescence vs. adulthood [31]).
Therefore, increases inMRs cannot be generalized to all types of chronic
stress situations. The increases inMRs found in our studymight be relat-
ed to compensatorymechanismsdeveloped in stressed agedmice. It has
been described that glucocorticoid actions upon theMRprotect neurons
in stress. MR activation enhances the induction of LTP in hippocampus
[32]. Therefore, the increased levels of MR found in this studymight re-
ﬂect compensatory changes occurring so as to alleviate the loss of GRs,
as already shown in AD [33]. However, these increases in MR could
also contribute to the classical GR blockade/downregulation-associated
cognitive deﬁcits. Supporting this hypothesis, a recent clinical study re-
ported that long term memory was enhanced in healthy volunteers re-
ceiving the MR antagonist spironolactone [34].
Exposure to stress levels of glucocorticoids produces physiological
responses that are characteristic of insulin resistance. Among the differ-
ent mechanisms that have been suggested to be responsible for insulin
resistance in stress [35], our results point to a central role of JNK. JNK, as
a member of the MAPK family, is a central stress signaling pathway in-
volved in neuronal plasticity, regeneration, cell death and regulation
of cellular senescence [36,37]. JNK may directly induce insulin resis-
tance [38] because JNK phosphorylates IRS1 at an inhibitory site that
can block signal transduction by the insulin receptor [24]. Even though
increased peripheral levels of insulin do not necessarily reﬂect its levels
in the brain, both reduced insulin receptor phosphorylation and the
signiﬁcant reduction in IRS1 phosphorylation status (at the active
Ser636/639 site) suggest that insulin signaling-dependent effects are
inhibited in CMS aged mice, as already suggested in AD [39,40]. It has
even been suggested that cognitive impairment in diabetes may be a
glucocorticoid-mediated effect because an elevation of circulatingcorticosterone is thought to be associated with memory impairments
[10–12].
The insulin signal transduction cascade of the Akt/GSK3β pathway
promotes neuronal survival by directly inactivating the proapoptotic
machinery. Interestingly, this is one of the main routes required for
the induction of long-term potentiation and depression, basic processes
underlying learning andmemory [41]. In this regard, clinical and epide-
miological studies suggest that diabetes and hyperinsulinemia are fac-
tors that are suspected of increasing the risk of developing AD [42].
Through dysregulation of GSK3β, dysfunction of the insulin receptor fa-
cilitates tau hyperphosphorylation [43], which forms neuroﬁbrillary
tangles in AD. Supporting our hypothesis regarding the involvement
of JNK, Akt and tau have been shown to be important substrates of
JNK [44]. Previous studies have also reported the association between
the hyperphosphorylation of tau and stress and stress-activated kinases
[45,46]. The alterations found in this study in another signal cascade
activated by the insulin receptor, the ERK1/2 pathway, may also be con-
tributing to the stress-associatedmemory deﬁcits. ERK1/2 play essential
roles in neuronal survival [47] and synaptic plasticity related to learning
and memory formation [48]. Altogether, alterations in insulin activated
pathways might contribute to cognitive deﬁcits in stressed aged mice.
On one hand, clinical studies report a strong correlation between the
extent of tau hyperphosphorylation and severity of impairments of
memory [49,50]. On the other hand, previous work demonstrated an
absolute requirement for ERK activity in the induction of LTP [51] and
memory consolidation [52].
The principal constituent of amyloid plaques observed in AD is the
Aβ protein, which is generated from APP. APP can be cleaved by
BACE1 and α-secretase to produce C99 and C83. These C-terminal frag-
ments can then be cleaved by γ-secretase to produce Aβ and p3, respec-
tively [14]. It has been shown experimentally that stress/increased
corticosterone levels provoke misprocessing of amyloid precursor
2338 M. Solas et al. / Biochimica et Biophysica Acta 1832 (2013) 2332–2339peptide in the rat hippocampus, resulting in increased levels of Aβ
[15,22,53] and potentiating the deleterious effects of Aβ on neuronal
survival [46]. In transgenic mouse models of AD [16,17], it has also
been shown that chronic stress or elevated glucocorticoid levels poten-
tiate Aβ deposition and induce cognitive deﬁcits. In recent studies car-
ried out on chronically stressed adult animals it has been reported
that animals sensitive to stress, and not those resistant to stress, also
show increased Aβ and BACE1 levels [54]. In our study, even though
increases in Aβ levels did not reach statistical signiﬁcance (probably
due to the small number of data associated to increased mortality in
the CMS aged group), there was an increase in the amyloidogenic pro-
cessing of APP in CMS aged mice, as shown by increased C99:C83 ratio
and increased expression of BACE1, that were not accompanied by
changes in the expression of APP. However, it should be noted that
the ratio C99:C83 is increased only in CMS aged mice when compared
to controls, and no differences with the aged mice were found.
Therefore, a contribution of aging independent from stress cannot be
discarded. C99 has intrinsic neurotoxic properties [55], causes synaptic
degeneration [56] and impairs long-term potentiation [57] and cogni-
tion [58], although all these effects are most probably due to enhanced
Aβ generation.
Interestingly, it has been reported that JNKmediates BACE1 upregu-
lation [59,60]. Understanding these interactions would be important
given that the tau hyperphosphorylation and pathology are also trig-
gered by misprocessing of APP into Aβ [61–63]. Therefore, JNK activa-
tion might constitute the link by which stress interferes with both
amyloidogenic processing and tau phosphorylation. In this sense, the
activation of JNK has been associated with age-dependent amyloid
plaque deposition and tau phosphorylation in a Tg2576/PS1 double
transgenic mouse [23,64,65].
Altogether, the present data further support the idea that endoge-
nous (age) and exogenous factors (stress)might be important determi-
nants of the onset and progress of AD. However, the results of this study
should be cautiously considered because of the small sample size. From
our results, a tentative mechanism could be hypothesized by which
glucocorticoids, through an activation of JNK, inactivate the insulin
receptor-mediated pathways.
Disclosure statement
All authors disclose any actual or potential conﬂict of interest includ-
ing any ﬁnancial, personal or other relationships with other people or
organizations within three years of beginning the work submitted that
could inappropriately inﬂuence (bias) this work.
Acknowledgements
The authors are thankful for the helpful discussions that were held
with Dr Rafael Franco. This study has been supported by a grant from
FIS (10/01748) and “Tu eliges, Tu decides” projects of CAN. Maite
Solas has a scholarship fromMinisterio de Educación y Ciencia (Spain).
References
[1] B.S. McEwen, Sex, stress and the hippocampus: allostasis, allostatic load and the
aging process, Neurobiol. Aging 23 (2002) 921–939.
[2] D.B. Miller, J.P. O'Callaghan, Neuroendocrine aspects of the response to stress,
Metabolism 51 (2002) 5–10.
[3] R.L. Ownby, E. Crocco, A. Acevedo, V. John, D. Loewenstein, Depression and risk for
Alzheimer disease: systematic review, meta-analysis, and metaregression analysis,
Arch. Gen. Psychiatry 63 (2002) 530–538.
[4] R.S. Wilson, L.L. Barnes, D.A. Bennett, Y. Li, J.L. Bienias, C.F. Mendes de Leon, D.A.
Evans, Proneness to psychological distress and risk of Alzheimer disease in a biracial
community, Neurology 64 (2005) 380–382.
[5] A. Armario, The hypothalamic–pituitary–adrenal axis: what can it tell us about
stressors? CNS Neurol. Disord. Drug Targets 5 (2006) 485–501.
[6] R.M. Sapolsky, L.C. Krey, B.S. McEwen, The adrenocortical stress-response in the
aged male rat: impairment of recovery from stress, Exp. Gerontol. 18 (1983) 55–64.[7] B.M. Kudielka, A.K. Schmidt-Reinwald, D.H. Hellhammer, T. Schürmeyer, C.
Kirschbaum, Psychosocial stress and HPA functioning: no evidence for a reduced re-
silience in healthy elderly men, Stress 3 (2000) 229–420.
[8] B.S. McEwen, Stress and the aging hippocampus, Front. Neuroendocrinol. 20 (1999)
49–70.
[9] G.G. Piroli, C.A. Grillo, L.R. Reznikov, S. Adams, B.S. McEwen, M.J. Charron, L.P.
Reagan, Corticosterone impairs insulin-stimulated translocation of GLUT4 in the
rat hippocampus, Neuroendocrinology 85 (2007) 71–80.
[10] B. Aisa, R. Tordera, B. Lasheras, J. Del Río, M.J. Ramírez, Cognitive impairment
associated to HPA axis hyperactivity after maternal separation in rats,
Psychoneuroendocrinology 32 (2007) 256–266.
[11] D. Coluccia, O.T. Wolf, S. Kollias, B. Roozendaal, A. Forster, D.J. de Quervain, Glucocor-
ticoid therapy-inducedmemory deﬁcits: acute versus chronic effects, J. Neurosci. 28
(2008) 3474–3478.
[12] H.C. Abercrombie, A.L. Jahn, R.J. Davidson, S. Kern, C. Kirschbaum, J. Halverson,
Cortisol's effects on hippocampal activation in depressed patients are related to
alterations in memory formation, J. Psychiatr. Res. 45 (2011) 15–23.
[13] R.M. Sapolsky, Glucocorticoid toxicity in the hippocampus: temporal aspects of
neuronal vulnerability, Brain Res. 359 (1985) 300–305.
[14] V. Dhikav, K.S. Anand, Glucocorticoids may initiate Alzheimer's disease: a potential
therapeutic role for mifepristone (RU-486), Med. Hypotheses 68 (2007) 1088–1092.
[15] C. Catania, I. Sotiropoulos, R. Silva, C. Onofri, K.C. Breen, N. Sousa, O.F. Almeida, The
amyloidogenic potential and behavioral correlates of stress, Mol. Psychiatry 14
(2009) 95–105.
[16] K.N. Green, L.M. Billings, B. Roozendaal, J.L. McGaugh, F.M. LaFerla, Glucocorticoids
increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease,
J. Neurosci. 26 (2006) 9047–9056.
[17] Y.H. Jeong, C.H. Park, J. Yoo, K.Y. Shin, S.M. Ahn, H.S. Kim, S.H. Lee, P.C. Emson, Y.H.
Suh, Chronic stress accelerates learning and memory impairments and increases
amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease
model, FASEB J. 20 (2006) 729–731.
[18] A. Harkin, D.D. Houlihan, J.P. Kelly, Reduction in preference for saccharin by repeated
unpredictable stress in mice and its prevention by imipramine, J. Psychopharmacol.
16 (2002) 115–123.
[19] N. Elizalde, F.J. Gil-Bea, M.J. Ramírez, B. Aisa, B. Lasheras, J. Del Rio, R.M. Tordera,
Long-lasting behavioral effects and recognition memory deﬁcit induced by chronic
mild stress in mice: effect of antidepressant treatment, Psychopharmacology 199
(2008) 1–14.
[20] A.M. Flanagan, J.L. Brown, C.A. Santiago, P.Y. Aad, L.J. Spicer, M.T. Spicer, High-fat
diets promote insulin resistance through cytokine gene expression in growing
female rats, J. Nutr. Biochem. 19 (2008) 505–513.
[21] J. Ribot, A.M. Rodríguez, E. Rodríguez, A. Palou, Adiponectin and resistin response in
the onset of obesity in male and female rats, Obesity 16 (2008) 723–730.
[22] M. Solas, B. Aisa, M.C. Mugueta, J. Del Río, R.M. Tordera, M.J. Ramírez, Interactions
between age, stress and insulin on cognition: implications for Alzheimer's disease,
Neuropsychopharmacology 35 (2010) 1664–1673.
[23] J.M. Kyriakis, Signaling by the germinal center kinase family of protein kinases,
J. Biol. Chem. 274 (1999) 5259–5262.
[24] G. Sabio, M. Das, A. Mora, Z. Zhang, J.Y. Jun, H.J. Ko, T. Barrett, J.K. Kim, R.J. Davis, A
stress signaling pathway in adipose tissue regulates hepatic insulin resistance,
Science 322 (2008) 1539–1543.
[25] E.M. Mandelkow, G. Drewes, J. Biernat, N. Gustke, J. Van Lint, J.R. Vandenheede, E.
Mandelkow, Glycogen synthase kinase-3 and the Alzheimer-like state of
microtubule-associated protein tau, FEBS Lett. 314 (1992) 315–321.
[26] V. Sterlemann, G. Rammes, M. Wolf, C. Liebl, K. Ganea, M.B. Müller, M.V. Schmidt,
Chronic social stress during adolescence induces cognitive impairment in aged
mice, Hippocampus 20 (2010) 540–549.
[27] C. Sandi, K. Tourayot, Mid-life stress and cognitive deﬁcits during early aging in rats:
individual differences and hippocampal correlates, Neurobiol. Aging 27 (2006)
128–140.
[28] E. Borcel, L. Pérez-Alvarez, A.I. Herrero, T. Brionne, E. Varea, V. Berezin, E. Bock, C.
Sandi, C. Venero, Chronic stress in adulthood followed by intermittent stress impairs
spatial memory and the survival of newborn hippocampal cells in aging animals:
prevention by FGL, a peptide mimetic of neural cell adhesion molecule, Behav.
Pharmacol. 19 (2008) 41–49.
[29] E.K. Murphy, R.L. Spencer, K.J. Sipe, J.P. Herman, Decrements in nuclear glucocorti-
coid receptor (GR) protein levels and DNA binding in aged rat hippocampus, Endo-
crinology 143 (2002) 1362–1370.
[30] M.V. Schmidt, S.H. Scharf, V. Sterlemann, K. Ganea, C. Liebl, F. Holsboer, M.B. Müller,
High susceptibility to chronic social stress is associated with a depression-like phe-
notype, Psychoneuroendocrinology 35 (2010) 635–643.
[31] Z. Xu, Y. Zhang, B. Hou, Y. Gao, Y. Wu, C. Zhang, Chronic corticosterone administra-
tion from adolescence through early adulthood attenuates depression-like behav-
iors in mice, J. Affect. Disord. 131 (2011) 128–135.
[32] M. Joëls, E. Van Riel, Mineralocorticoid and glucocorticoid receptor-mediated effects
on serotonergic transmission in health and disease, Ann. N. Y. Acad. Sci. 1032 (2004)
301–303.
[33] F.J. Gil-Bea, B. Aisa, A. Solomon, M. Solas, M.C. Mugueta, B. Winblad, M. Kivipelto, A.
Cedazo-Mínguez, M.J. Ramírez, HPA axis dysregulation associated to apolipoprotein
E4 genotype in Alzheimer's disease, J. Alzheimers Dis. 22 (2010) 829–838.
[34] S. Cornelisse, M. Joëls, T. Smeets, A randomized trial on mineralocorticoid receptor
blockade in men: effects on stress responses, selective attention, and memory,
Neuropsychopharmacology 36 (2011) 2720–2728.
[35] J.M. Amatruda, J.N. Livingston, D.H. Lockwood, Cellular mechanisms in selected
states of insulin resistance: human obesity, glucocorticoid excess, and chronic
renal failure, Diabetes Metab. Rev. 1 (1985) 293–317.
2339M. Solas et al. / Biochimica et Biophysica Acta 1832 (2013) 2332–2339[36] D. Kögel, R. Schomburg, E. Copanaki, J.H. Prehn, Regulation of gene expression by the
amyloid precursor protein: inhibition of the JNK/c-Jun pathway, Cell Death Differ. 12
(2005) 1–9.
[37] J. Maruyama, I. Naguro, K. Takeda, H. Ichijo, Stress-activated MAP kinase cascades in
cellular senescence, Curr. Med. Chem. 16 (2009) 1229–1235.
[38] C.R. Weston, R.J. Davis, The JNK signal transduction pathway, Curr. Opin. Cell Biol. 19
(2007) 142–149.
[39] S.M. de la Monte, J.R. Wands, Review of insulin and insulin-like growth factor ex-
pression, signaling, and malfunction in the central nervous system: relevance to
Alzheimer's disease, J. Alzheimers Dis. 7 (2005) 45–61.
[40] M. Jimenez-Palomares, J.J. Ramos-Rodriguez, J.F. Lopez-Acosta, M. Pacheco-Herrero,
A.M. Lechuga-Sancho, G. Perdomo, M. Garcia-Alloza, I. Cozar-Castellano, Increased
Aβ production prompts the onset of glucose intolerance and insulin resistance,
Am. J. Physiol. Endocrinol. Metab. 302 (2012) E1373–E1380.
[41] L.P. van der Heide, G.M. Ramakers, M.P. Smidt, Insulin signaling in the central ner-
vous system: learning to survive, Prog. Neurobiol. 79 (2006) 205–221.
[42] E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R. Wands,
S.M. de la Monte, Impaired insulin and insulin-like growth factor expression and
signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? J. Alzheimers
Dis. 7 (2005) 63–80.
[43] M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert, T. Kondo, J. Alber,
N. Galldiks, E. Küstermann, S. Arndt, A.H. Jacobs, W. Krone, C.R. Kahn, J.C. Brüning,
Role for neuronal insulin resistance in neurodegenerative diseases, Proc. Natl.
Acad. Sci. U. S. A. 101 (2004) 3100–3105.
[44] M.A. Bogoyevitch, B. Kobe, Uses for JNK: the many and varied substrates of the c-Jun
N-terminal kinases, Microbiol. Mol. Biol. Rev. 70 (2006) 1061–1095.
[45] Y.A. El-Faramawy, M.H. El-Banouby, P. Sergeev, A.K. Mortagy, M.S. Amer, A.M.
Abdel-Tawab, Changes in glutamate decarboxylase enzyme activity and tau-protein
phosphorylation in the hippocampus of old rats exposed to chronic mild stress: re-
versal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole, Pharmacol.
Biochem. Behav. 91 (2009) 339–344.
[46] I. Sotiropoulos, C. Catania, T. Riedemann, J.P. Fry, K.C. Breen, T.M. Michaelidis, O.F.
Almeida, Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in rat
neuronal cells expressing human tau, J. Neurochem. 107 (2008) 385–397.
[47] Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, M.E. Greenberg, Opposing effects of ERK
and JNK-p38 MAP kinases on apoptosis, Science 270 (1995) 1326–1331.
[48] S. Davis, S. Laroche, Mitogen-activated protein kinase/extracellular regulated kinase
signaling and memory stabilization: a review, Genes Brain Behav. 5 (2006) 61–72.
[49] M. Ewers, K. Buerger, S.J. Teipel, P. Scheltens, J. Schröder, R.P. Zinkowski, F.H.
Bouwman, P. Schönknecht, N.S. Schoonenboom, N. Andreasen, A. Wallin, J.F.
DeBernardis, D.J. Kerkman, B. Heindl, K. Blennow, H. Hampel, Multicenter assess-
ment of CSF-phosphorylated tau for the prediction of conversion of MCI, Neurology
69 (2007) 2205–2212.
[50] A.E. van der Vlies, N.A. Verwey, F.H. Bouwman, M.A. Blankenstein, M. Klein, P.
Scheltens, W.M. van der Flier, CSF biomarkers in relationship to cognitive proﬁles
in Alzheimer disease, Neurology 72 (2009) 1056–1061.
[51] J.D. English, J.D. Sweatt, Activation of p42 mitogen-activated protein kinase in
hippocampal long term potentiation, J. Biol. Chem. 271 (1996) 24329–24332.[52] K.L. Eckel-Mahan, T. Phan, S. Han, H. Wang, G.C. Chan, Z.S. Scheiner, D.R. Storm,
Circadian oscillation of hippocampal MAPK activity and cAmp: implications for
memory persistence, Nat. Neurosci. 11 (2008) 1074–1082.
[53] K. Ploj, E. Roman, I. Nylander, Long-term effects of maternal separation on ethanol
intake and brain opioid and dopamine receptors in male Wistar rats, Neuroscience
121 (2003) 787–799.
[54] A. Briones, S. Gagno, E. Martisova, M. Dobarro, B. Aisa, M. Solas, R. Tordera, M.J.
Ramírez, Stress-induced anhedonia is associated with an increase in Alzheimer's
disease-related markers, Br. J. Pharmacol. 165 (2012) 897–907.
[55] B.A. Yankner, L.R. Dawes, S. Fisher, L. Villa-Komaroff, M.L. Oster-Granite, R.L. Neve,
Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's
disease, Science 245 (1989) 417–420.
[56] M.L. Oster-Granite, D.L. McPhie, J. Greenan, R.L. Neve, Age-dependent neuronal and
synaptic degeneration in mice transgenic for the C terminus of the amyloid precur-
sor protein, J. Neurosci. 16 (1996) 6732–6741.
[57] J. Nalbantoglu, G. Tirado-Santiago, A. Lahsaïni, J. Poirier, O. Goncalves, G. Verge, F.
Momoli, S.A. Welner, G. Massicotte, J.P. Julien, M.L. Shapiro, Impaired learning and
LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor
protein, Nature 387 (1997) 500–505.
[58] J. Berger-Sweeney, D.L. McPhie, J.A. Arters, J. Greenan, M.L. Oster-Granite, R.L. Neve,
Impairments in learning and memory accompanied by neurodegeneration in mice
transgenic for the carboxyl-terminus of the amyloid precursor protein, Mol. Brain
Res. 66 (1999) 150–162.
[59] E. Tamagno, M. Parola, P. Bardini, A. Piccini, R. Borghi, M. Guglielmotto, G. Santoro, A.
Davit, O. Danni, M.A. Smith, G. Perry, M. Tabaton, Beta-site APP cleaving enzyme
up-regulation induced by 4-hydroxynonenal ismediated by stress-activated protein
kinases pathways, J. Neurochem. 92 (2005) 628–636.
[60] E. Tamagno, M. Guglielmotto, L. Giliberto, A. Vitali, R. Borghi, R. Autelli, O. Danni, M.
Tabaton, JNK and ERK1/2 pathways have a dual opposite effect on the expression of
BACE1, Neurobiol. Aging 30 (2009) 1563–1573.
[61] A. Takashima, T. Honda, K. Yasutake, G. Michel, O. Murayama, M. Murayama, K.
Ishiguro, H. Yamaguchi, Activation of tau protein kinase I/glycogen synthase
kinase-3beta by amyloid beta peptide (25–35) enhances phosphorylation of tau in
hippocampal neurons, Neurosci. Res. 31 (1998) 317–323.
[62] K. Ghosal, D.L. Vogt, M. Liang, Y. Shen, B.T. Lamb, S.W. Pimplikar, Alzheimer's
disease-like pathological features in transgenic mice expressing the APP intracellu-
lar domain, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 18367–18372.
[63] O.A. Shipton, J.R. Leitz, J. Dworzak, C.E. Acton, E.M. Tunbridge, F. Denk, H.N. Dawson,
M.P. Vitek, R. Wade-Martins, O. Paulsen, M. Vargas-Caballero, Tau protein is re-
quired for amyloid {beta}-induced impairment of hippocampal long-term potentia-
tion, J. Neurosci. 31 (2011) 1688–1692.
[64] A.G. Pearson, U.T. Byrne, G.A. MacGibbon, R.L. Faull, M. Dragunow, Activated c-Jun is
present in neuroﬁbrillary tangles in Alzheimer's disease brains, Neurosci. Lett. 398
(2006) 246–250.
[65] B. Puig, T. Gómez-Isla, E. Ribé, M. Cuadrado, B. Torrejón-Escribano, E. Dalfó, I. Ferrer,
Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and
p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA
plaques in APP Tg2576 mice, Neuropathol. Appl. Neurobiol. 30 (2004) 491–502.
